BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 33711943)

  • 41. NT -pro BNP as a Mediator of the Racial Difference in Incident Atrial Fibrillation and Heart Failure.
    Whitman IR; Vittinghoff E; DeFilippi CR; Gottdiener JS; Alonso A; Psaty BM; Heckbert SR; Hoogeveen RC; Arking DE; Selvin E; Chen LY; Dewland TA; Marcus GM
    J Am Heart Assoc; 2019 Apr; 8(7):e010868. PubMed ID: 30912456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
    Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
    Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical and echocardiographic characteristics of individuals aged 75/76 years old with screening-detected elevated NT-proBNP levels.
    Al-Khalili F; Kemp-Gudmundsdottir K; Svennberg E; Fredriksson T; Frykman V; Friberg L; Rosenqvist M; Engdahl J
    Open Heart; 2020; 7(1):e001200. PubMed ID: 32153793
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of frequent supraventricular extrasystoles and a high CHADS2 score to predict first-time appearance of atrial fibrillation.
    Suzuki S; Sagara K; Otsuka T; Kano H; Matsuno S; Takai H; Uejima T; Oikawa Y; Koike A; Nagashima K; Kirigaya H; Yajima J; Tanabe H; Sawada H; Aizawa T; Yamashita T
    Am J Cardiol; 2013 Jun; 111(11):1602-7. PubMed ID: 23499279
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relation of N-terminal pro-brain natriuretic peptide and new-onset atrial fibrillation in patients with acute coronary syndrome: a systematic review and meta-analysis.
    Gao X; Zeng R; Liao P; Zhu H; Zhang M
    Scand J Clin Lab Invest; 2016 Oct; 76(6):460-4. PubMed ID: 27347749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies.
    Sinner MF; Stepas KA; Moser CB; Krijthe BP; Aspelund T; Sotoodehnia N; Fontes JD; Janssens AC; Kronmal RA; Magnani JW; Witteman JC; Chamberlain AM; Lubitz SA; Schnabel RB; Vasan RS; Wang TJ; Agarwal SK; McManus DD; Franco OH; Yin X; Larson MG; Burke GL; Launer LJ; Hofman A; Levy D; Gottdiener JS; Kääb S; Couper D; Harris TB; Astor BC; Ballantyne CM; Hoogeveen RC; Arai AE; Soliman EZ; Ellinor PT; Stricker BH; Gudnason V; Heckbert SR; Pencina MJ; Benjamin EJ; Alonso A
    Europace; 2014 Oct; 16(10):1426-33. PubMed ID: 25037055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incremental predictive value of pre-procedural N-terminal pro-B-type natriuretic peptide for short-term recurrence in atrial fibrillation ablation.
    Hwang HJ; Son JW; Nam BH; Joung B; Lee B; Kim JB; Lee MH; Jang Y; Chung N; Shim WH; Cho SY; Kim SS
    Clin Res Cardiol; 2009 Apr; 98(4):213-8. PubMed ID: 19229464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. B-type natriuretic peptide level after sinus rhythm restoration in patients with persistent atrial fibrillation - clinical significance.
    Wozakowska-Kapłon B; Bartkowiak R; Grabowska U; Janiszewska G
    Kardiol Pol; 2010 Jul; 68(7):781-6. PubMed ID: 20648436
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure.
    Dini FL; Gabutti A; Passino C; Fontanive P; Emdin M; De Tommasi SM
    Int J Cardiol; 2010 Apr; 140(3):344-50. PubMed ID: 19128846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Repeated Measurements of Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Assess Long-Term Mortality Risk in Subjects with Osteoarthritis.
    Rehm M; Büchele G; Brenner RE; Günther KP; Brenner H; Koenig W; Rothenbacher D
    Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33562838
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicting the outcome of hip fracture patients by using N-terminal fragment of pro-B-type natriuretic peptide.
    Nordling P; Kiviniemi T; Strandberg M; Strandberg N; Airaksinen J
    BMJ Open; 2016 Feb; 6(2):e009416. PubMed ID: 26911583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Raised plasma aldosterone and natriuretic peptides in atrial fibrillation.
    Dixen U; Ravn L; Soeby-Rasmussen C; Paulsen AW; Parner J; Frandsen E; Jensen GB
    Cardiology; 2007; 108(1):35-9. PubMed ID: 16968988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study.
    Patton KK; Ellinor PT; Heckbert SR; Christenson RH; DeFilippi C; Gottdiener JS; Kronmal RA
    Circulation; 2009 Nov; 120(18):1768-74. PubMed ID: 19841297
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum N-terminal-pro-brain natriuretic peptide level and its clinical implications in patients with atrial fibrillation.
    Bai M; Yang J; Li Y
    Clin Cardiol; 2009 Dec; 32(12):E1-5. PubMed ID: 20014208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk prediction of atrial fibrillation in the community combining biomarkers and genetics.
    Börschel CS; Ohlrogge AH; Geelhoed B; Niiranen T; Havulinna AS; Palosaari T; Jousilahti P; Rienstra M; van der Harst P; Blankenberg S; Zeller T; Salomaa V; Schnabel RB
    Europace; 2021 May; 23(5):674-681. PubMed ID: 33458771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: Association with atrial fibrillation progression phenotypes.
    Büttner P; Schumacher K; Dinov B; Zeynalova S; Sommer P; Bollmann A; Husser D; Hindricks G; Kornej J
    Heart Rhythm; 2018 Aug; 15(8):1132-1137. PubMed ID: 29604419
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Associations of High-Sensitivity Cardiac Troponin and Natriuretic Peptide With Subsequent Risk of Infection in Persons Without Cardiovascular Disease: The Atherosclerosis Risk in Communities Study.
    Ishigami J; Hoogeveen RC; Ballantyne CM; Folsom AR; Coresh J; Selvin E; Matsushita K
    Am J Epidemiol; 2019 Dec; 188(12):2146-2155. PubMed ID: 31063194
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Interplay between Fasting Glucose, Echocardiography, and Biomarkers: Pathophysiological Considerations and Prognostic Implications.
    Pareek M
    Dan Med J; 2017 Sep; 64(9):. PubMed ID: 28874244
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes.
    Resl M; Clodi M; Vila G; Luger A; Neuhold S; Wurm R; Adlbrecht C; Strunk G; Fritzer-Szekeres M; Prager R; Pacher R; Hülsmann M
    Heart; 2016 Dec; 102(24):1963-1968. PubMed ID: 27456261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure.
    Aimo A; Januzzi JL; Mueller C; Mirò O; Pascual Figal DA; Jacob J; Herrero-Puente P; Llorens P; Wussler D; Kozhuharov N; Sabti Z; Breidthardt T; Vergaro G; Ripoli A; Prontera C; Saccaro L; Passino C; Emdin M
    Int J Cardiol; 2019 Oct; 293():137-142. PubMed ID: 31200964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.